Organogenesis (ORGO) Expected to Post Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is expected to be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $54.2740 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.08). The company had revenue of $37.23 million during the quarter, compared to analysts’ expectations of $43.26 million. Organogenesis had a positive return on equity of 9.63% and a negative net margin of 0.84%.

Organogenesis Trading Down 1.3%

Shares of Organogenesis stock opened at $2.34 on Tuesday. The firm has a market cap of $301.11 million, a price-to-earnings ratio of -12.32 and a beta of 1.34. The business has a 50-day moving average price of $2.45 and a 200-day moving average price of $2.80. The company has a quick ratio of 3.16, a current ratio of 3.53 and a debt-to-equity ratio of 0.05. Organogenesis has a twelve month low of $2.04 and a twelve month high of $7.08.

Hedge Funds Weigh In On Organogenesis

Several large investors have recently modified their holdings of ORGO. Invesco Ltd. raised its holdings in Organogenesis by 9.9% during the 4th quarter. Invesco Ltd. now owns 175,219 shares of the company’s stock valued at $908,000 after buying an additional 15,790 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in Organogenesis during the fourth quarter worth $57,000. XTX Topco Ltd bought a new position in Organogenesis during the fourth quarter valued at $79,000. Oxford Asset Management LLP purchased a new stake in shares of Organogenesis in the fourth quarter valued at $66,000. Finally, Millennium Management LLC raised its stake in shares of Organogenesis by 481.2% in the fourth quarter. Millennium Management LLC now owns 483,742 shares of the company’s stock valued at $2,506,000 after acquiring an additional 400,514 shares during the period. Institutional investors own 49.57% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ORGO. UBS Group set a $3.00 price target on Organogenesis in a research note on Thursday, May 28th. Weiss Ratings downgraded Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. BTIG Research cut Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Wall Street Zen upgraded Organogenesis from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Finally, Truist Financial initiated coverage on shares of Organogenesis in a report on Thursday, May 28th. They issued a “hold” rating and a $3.00 target price for the company. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Organogenesis currently has a consensus rating of “Hold” and an average price target of $5.75.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.